Can Immune X help prevent the common cold in healthy adults?
Official title: The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Run by Givaudan France Naturals · NCT07787130 · Data updated 2026-11-12
This trial tests whether taking Immune X daily for 16 weeks during winter can reduce how often healthy adults with a history of colds get a cold, compared with a placebo.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Givaudan France Naturals Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dijon, Côte-d'Or) |
| Status | Recruiting |
| Started | October 9, 2026 |
| Main results expected | March 1, 2027 |
| Study ends | March 1, 2027 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07787130 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with a history of at least two upper respiratory infections in the previous winter.
✕Probably not a fit
Individuals who do not experience a reduction in cold frequency or severity with Immune X may derive no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Healthy adults aged 18–65 with a recent history of upper respiratory infections will take Immune X or a placebo daily for 16 weeks during winter. The study will compare the proportion of participants with at least one clinically confirmed cold and will examine the number, duration, and severity of cold episodes. Participants will complete questionnaires, keep symptom records on a smartphone app, and provide blood and stool samples, with visits at the start and end of the study. The trial is conducted at CEN Expérimental in Dijon, France, sponsored by Givaudan France Naturals with collaborators from CEN Expérimental.
Why it matters
Potential benefit: Participants may experience fewer or milder cold episodes if Immune X is effective.
How similar studies have gone: Previous research with immune-modulating approaches has shown mixed results; this study tests a specific product in a defined population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged 18 to 65 years. * History of at least two upper respiratory tract infections during the previous winter season. * Body mass index between 18 and 30 kg/m². * Generally healthy, as determined by the investigator. * Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study. * Covered by French health insurance. * Able and willing to provide written informed consent. Exclusion Criteria: * Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment. * Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment. * Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment. * Use of systemic antibiotics within 3 months before enrollment. * Receipt of any vaccination within 6 weeks before enrollment. * Surgery requiring general anesthesia within 1 month before enrollment. * History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease. * Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis. * Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID. * Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism. * Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management. * Untreated or inadequately controlled diabetes. * History or current diagnosis of periodontitis. * Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids. * Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program. * Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment. * Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment. * Current drug or alcohol abuse, or a history of abuse within the previous 12 months. * Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study. * Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study. * More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study. * Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results. * Current participation in another clinical trial or being in an exclusion period from a previous clinical trial. * Pregnant or breastfeeding. * Persons deprived of liberty, under legal protection, or unable to provide informed consent. * Individuals who have reached the regulatory compensation limit for participation in clinical research.
Where it's running
-
CEN Expérimental
Dijon, Côte-d'Or, France Recruiting
Study contacts
- Principal investigator: Carole Perrin, MD — CEN Expérimental
- Study coordinator: Katja A. Schönenberger, PhD
- Email: katja.schoenenberger@givaudan.com
- Phone: +41 52 354 01 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating Antiwei Granules for treating the common cold
This study tests if Antiwei granules can help adults with the common cold feel better compared to a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.